Possible new Alzheimer's biomarker uncovered; Nipro wins FDA clearance for two blood glucose monitoring systems;

> Researchers from the Blanchette Rockefeller Neurosciences Institute at West Virginia University may have found a new Alzheimer's disease biomarker. Story

> The Mayo Clinic is the first health system to offer Exact Sciences' ($EXAS) new Cologuard test, a noninvasive stool DNA screening diagnostic for colorectal cancer recently approved by the FDA. Release

> Nipro Diagnostics gained FDA clearance for two new blood glucose monitoring systems. Release

> Medical diagnostics company Vermillion ($VRML) has named a PerkinElmer ($PKI) veteran as its new vice president of sales and managed markets as part of a restructuring effort. Story

> New Jersey's Cancer Genetics ($CGIX) will work with a researcher from Keck Medicine of the University of Southern California to identify and evaluate biomarkers to help measure the prognosis of a form of lymphoma. Release

Suggested Articles

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.